Welcome, Guest. Please login or register.
May 26, 2024, 11:22:06 am

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 98
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 42
Total: 42


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA Approves New Hep C Drug: Olysio (Simeprevir)  (Read 10317 times)

0 Members and 1 Guest are viewing this topic.

Offline iana5252

  • Administrator
  • Member
  • Posts: 187
FDA Approves New Hep C Drug: Olysio (Simeprevir)
« on: November 26, 2013, 09:14:55 am »
The U.S. Food and Drug Administration (FDA) has approved Janssen Therapeutics’ NS3/4A protease inhibitor Olysio (simeprevir) for the treatment of those with genotype 1 of hepatitis C virus (HCV) who have compensated liver disease, including cirrhosis. People who are treatment naive as well as those who have failed a previous attempt at a hep C cure may benefit from the drug, which is to be taken in combination with pegylated interferon and ribavirin.


Next up is Sovaldi (sofosbuvir). Hopefully in the next week or two.

Offline jberlin

  • Global Moderator
  • Member
  • Posts: 319
  • Contracted Hep C in 76, treated 2004 & 2012, cured
Re: FDA Approves New Hep C Drug: Olysio (Simeprevir)
« Reply #1 on: November 30, 2013, 01:19:27 am »
They are making such great strides, and this is more welcome news, but soon I hope we will have our 1st regimen that will not include interferon.  Fingers crossed. -jack


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.